Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Pfizer (NYSE:PFE) with a Market Perform ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The company's strong cash flow supports continued dividend growth and business ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of ...

The stock's rise snapped a three-day losing streak.

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Real-time index price for KBW Property & Casualty Index (KPX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The stock is now trading near Evercore's price target of $65, prompting the analysts to take a more cautious stance. “We are ...

In the latest market close, Pfizer (PFE) reached $29.08, with a -0.27% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.77%. Meanwhile, the Dow ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

The major U.S. stock market indexes are officially in overheated territory thanks to enthusiasm for artificial intelligence ...